Clinical trials
Idiopathic Pulmonary Fibrosis clinical trials
Below are recruiting idiopathic pulmonary fibrosis clinical trials, each written for real people, not researchers. We’re tracking 85 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03478553Recruiting
Study of genes in people with pulmonary fibrosis
This study looks at genetic (inherited) factors related to pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF). It may help researchers understand why some families are more affected and could guide future testing or treatments.
Aurora, ColoradoAges 18 years+ - NCT06909409Recruiting
Vitamin D and lung immune cells in lung fibrosis
This study looks at how vitamin D affects immune cells in the lungs of people with a lung scarring condition called idiopathic pulmonary fibrosis (IPF) or other similar lung diseases. It tests if vitamin D levels are linked to how these cells work.
Aarhus NAges 18 years+ - NCT07230288RecruitingPhase 2
Study of ABBV-142 for Idiopathic Pulmonary Fibrosis
This trial is testing a new antibody drug, ABBV-142, to see if it can reduce disease activity in adults with idiopathic pulmonary fibrosis (IPF). It may help if your IPF was diagnosed within the last 7 years and you meet certain health criteria.
Birmingham, AlabamaAges 40 years+ - NCT05098717Recruiting
PEEP settings guided by lung pressure in pulmonary fibrosis
This trial tests whether using lung-pressure measurements to adjust ventilator PEEP (a breathing-support setting that keeps airways open) can help people with pulmonary fibrosis who are on a breathing machine for acute respiratory failure. It may improve breathing comfort and oxygenation by finding the best PEEP level for you.
ModenaAges 18–90 - NCT07121413RecruitingPhase 2
Testing SV001 for Idiopathic Pulmonary Fibrosis
This trial tests a new drug called SV001 to see if it is safe and tolerable for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and meet certain health criteria, this study may help find new treatment options.
ChengduAges 40 years+ - NCT06756230Recruiting
Downhill walking exercise for IPF patients
This study tests whether downhill walking improves lung function and exercise ability in people with idiopathic pulmonary fibrosis (IPF). If you can walk on a treadmill and haven't been in a structured exercise program recently, you may qualify.
Istanbul, ÜsküdarAges 18–75 - NCT06968845RecruitingPhase 2
Study of LTI-03 for Idiopathic Pulmonary Fibrosis
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
Birmingham, AlabamaAges 40 years+ - NCT06951217RecruitingPhase 2
Long-term safety study of an inhaled drug for lung scarring
This study continues treatment for people who already completed a previous study with an Avalyn inhaled antifibrotic drug. It aims to check the long-term safety of the medication for patients with certain types of lung scarring.
Birmingham, AlabamaAges 18 years+ - NCT06853145RecruitingEarly Phase 1
Using a special MRI scan to study lung disease in IPF
This trial uses an advanced MRI technique with a special gas (hyperpolarized xenon-129) to look at lung function in people with idiopathic pulmonary fibrosis (IPF). It may help doctors better understand how the disease affects your lungs and could lead to improved care.
Charlottesville, VirginiaAges 18 years+ - NCT06747923RecruitingPhase 2
SB17170 for Idiopathic Pulmonary Fibrosis (IPF)
This trial tests a new drug, SB17170, for people with IPF. It aims to see if the drug can help slow down lung damage. You may be eligible if you have a confirmed diagnosis of IPF and meet certain lung function criteria.
GoyangAges 40 years+ - NCT06714123RecruitingPhase 2
Senicapoc for worsening lung scarring
This trial tests if the drug senicapoc can help people whose lung scarring (pulmonary fibrosis) is getting worse despite standard care. It aims to slow down the decline in lung function.
Aarhus NAges 18 years+ - NCT06644144Recruiting
P4O2: A study for people with lung scarring
This study is testing a new way to track lung scarring (fibrosis) over time in people with conditions like IPF, other fibrotic lung diseases, or early signs of scarring. It might help doctors understand how the disease changes.
Amsterdam, North HollandAges 18–80 - NCT06567717RecruitingPhase 2
Zinc and vitamin B3 supplement for IPF
This trial tests whether adding zinc and nicotinamide riboside (a vitamin B3-like supplement) to standard IPF treatment can help improve lung function. It is for people with IPF who are already seeing a lung doctor and live in certain states.
Los Angeles, CaliforniaAges 50 years+ - NCT06488638Recruiting
Beetroot juice supplement for lung fibrosis
This trial tests whether a beetroot juice drink (rich in nitrates) can help people with idiopathic pulmonary fibrosis breathe better and exercise more. It's a small pilot study to see if it's safe and worth studying further.
SouthamptonAges 18–85 - NCT05975983RecruitingPhase 2
Oral treatment test for idiopathic pulmonary fibrosis
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
Birmingham, AlabamaAges 40 years+ - NCT05989698Recruiting
Validating a wearable cough monitor (C-mo)
This study tests a wearable device (C-mo) that monitors coughing. It is for people of all ages who are currently coughing and can cooperate with wearing a small sensor on their belly for a short time.
AlfenaAges 2 years+ - NCT05842681Recruiting
Azithromycin for early worsening of idiopathic pulmonary fibrosis
This trial studies whether adding azithromycin to standard care can help people whose idiopathic pulmonary fibrosis is starting to flare up (worsen) in the early stages. It’s mainly for adults who are not very sick and cannot require intensive breathing support.
AsyutAges 18–80 - NCT05674994RecruitingPhase 3
Steroid versus placebo for sudden worsening of lung scarring
This Phase 3 trial studies whether glucocorticoid (steroid) medicine helps people with idiopathic pulmonary fibrosis (IPF) who have a sudden flare-up, compared with an inactive placebo. You may be helped if steroids improve breathing and recovery during these acute episodes, but the study is designed to test that clearly.
AngersAges 18 years+ - NCT05571059RecruitingPhase 2
Oral ifetroban for idiopathic pulmonary fibrosis
This trial tests an oral medication, ifetroban, to see if it can slow the progression of idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. It aims to improve breathing and lung function in patients with IPF.
La Mesa, CaliforniaAges 40 years+ - NCT05392881Recruiting
Lung disease biobank for adults followed at a university clinic
This study collects and stores samples and health information from adults being followed for interstitial lung disease or certain rare lung conditions. The goal is to help researchers study these diseases over time and improve future care.
Kansas City, KansasAges 18 years+ - NCT05382572Recruiting
Pulmonary fibrosis community registry for patients and families
This study builds a community registry to learn about people affected by pulmonary fibrosis and related lung conditions, including patients, caregivers, and close family. By joining, you help researchers better understand needs and experiences in the real world.
Chicago, IllinoisAges 18 years+ - NCT04965298RecruitingPhase 3
Lansoprazole add-on treatment for idiopathic pulmonary fibrosis
This Phase 3 study tests whether adding lansoprazole (a stomach acid medicine) can improve outcomes for people with idiopathic pulmonary fibrosis (IPF). You may already be on IPF “anti-fibrotic” medication, and the study checks if the added lansoprazole helps, compared with placebo.
Norwich, NorfolkAges 40 years+ - NCT05310669Recruiting
Tests breathing effort using a nasal pressure sensor in IPF
This study measures how hard you breathe using a gentle nasal pressure device in people with idiopathic pulmonary fibrosis (IPF). It may help doctors better understand breathing mechanics in IPF and guide future care.
ModenaAges 18 years+ - NCT03437486Recruiting
Family study for inherited lung scarring causes
This study looks at what causes familial (inherited) pulmonary fibrosis by studying relatives who are not yet diagnosed with the lung disease. You may help researchers understand risk and early changes in the lungs within families.
Nashville, TennesseeAges 40–75
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for idiopathic pulmonary fibrosis?
- Yes. Clin2 currently lists 85 recruiting idiopathic pulmonary fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a idiopathic pulmonary fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a idiopathic pulmonary fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.